Drug reference
Type 2 diabetes mellitus [not controlled by metformin alone, or by metformin in combination with other antidiabetic drugs (including insulin)] ▶BY MOUTH ▶Adult: 1 tablet twice daily, based on patient’s current metformin dose
PDF page 766
Scottish Medicines Consortium (SMC) decisions SMC No. 983/14 The Scottish Medicines Consortium has advised (August 2014) that dapagliflozin plus metformin (Xigduo ®) is accepted for restricted use within NHS Scotland in patients for whom a combination of dapagliflozin and metformin is an appropriate choice of therapy i.e when metformin alone does not provide adequate glycaemic control and a sulfonylurea is inappropriate, or in combination with insulin, when insulin and metformin does not provide adequate control, or in combination with a sulphonylurea, when a sulfonylurea and metformin does not provide adequate control.
PDF page 766
→Appendix 1: dapagliflozin. metformin
PDF page 766
Manufacturer advises avoid (increased risk of lactic acidosis).
PDF page 766
There can be variation in the licensing of different medicines containing the same drug. Tablet CAUTIONARY AND ADVISORY LABELS 21 ▶Xigduo (AstraZeneca UK Ltd) Dapagliflozin (as Dapagliflozin propanediol monohydrate) 5 mg, Metformin hydrochloride 850 mg Xigduo 5mg/850mg tablets | 56 tablet P £36.59 DT = £36.59 Dapagliflozin (as Dapagliflozin propanediol monohydrate) 5 mg, Metformin hydrochloride 1 gram Xigduo 5mg/1000mg tablets | 56 tablet P £36.59 DT = £36.59
PDF page 766
1 tablet twice daily, based on patient’s current
First-line fragment. Read the complete Indications and Dose section above.
PDF page 766
